You just read:

Relmada Therapeutics Reaches Midway Point in Dose Escalation for Phase One Study of Novel NMDA Receptor Antagonist d-Methadone

News provided by

Relmada Therapeutics, Inc.

Jan 13, 2015, 08:00 ET